[PLEASE SELECT THE “Add-Ins” TAB IN THE ABOVE TOOLBAR AND CLICK THE “FINALISE BI TEMPLATE” MACRO 
ICON] 
h-3899-steps after_en  
Aripiprazole Zentiva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
Notifications 
IssuedA 
affectedSmP
are issued 
Commissio
C (Summary 
for type I 
n decision 
of Product 
variations 
(CD) is 
Characteristi
and Article 
issued for 
cs), Annex 
61(3) 
procedures 
II, Labelling, 
notifications 
that affect 
PL (Package 
(unless part 
the terms 
Leaflet).  
of a group 
of the 
including a 
marketing 
type II 
authorisatio
variation or 
n (e.g. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
extension 
summary of 
application 
product 
or a 
characterist
worksharing 
ics, annex 
application)
II, 
. Opinions 
labelling, 
are issued 
package 
for all other 
leaflet). 
procedures. 
The CD is 
issued on 
issued 
within two 
months of 
the opinion 
for 
variations 
falling 
under the 
scope of 
Article 
23.1a(a) of 
Regulation 
(EU) No. 
712/2012, 
or within 
one year 
for other 
procedures. 
/ amended 
on 
IB/0019/G 
This was an application for a group of variations. 
23/11/2023 
Annex II and 
Page 2/7 
 
 
 
 
 
 
 
 
PL 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
IA/0017 
A.4 - Administrative change - Change in the name 
12/10/2022 
n/a 
and/or address of a manufacturer or an ASMF holder 
Page 3/7 
 
 
 
 
 
 
 
 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IB/0016 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/08/2022 
24/07/2023 
SmPC, Annex 
Section 4.8 of the SmPC has been updated to add “blood 
generic/hybrid/biosimilar products following 
II, Labelling 
prolactine decreased” in the tabulated list of all adverse 
assessment of the same change for the reference 
and PL 
reactions in line with the text of reference product. The PL 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
has been updated accordingly. 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/02/2021 
04/06/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IB/0014/G 
This was an application for a group of variations. 
23/07/2020 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/06/2020 
04/06/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
R/0012 
Renewal of the marketing authorisation. 
26/03/2020 
02/06/2020 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Aripiprazole Zentiva in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IB/0011 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/06/2019 
02/06/2020 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IG/1029 
A.5.b - Administrative change - Change in the name 
18/12/2018 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0009 
B.II.c.3.z - Change in source of an excipient or 
14/03/2018 
n/a 
reagent with TSE risk - Other variation 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/02/2018 
21/03/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0007 
B.I.b.2.a - Change in test procedure for AS or 
08/12/2017 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0006 
B.II.z - Quality change - Finished product - Other 
30/10/2017 
n/a 
variation 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/04/2017 
21/03/2018 
Annex II 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/12/2016 
13/02/2017 
SmPC and 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/07/2016 
13/02/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0002/G 
This was an application for a group of variations. 
17/03/2016 
13/02/2017 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0001 
A.5.b - Administrative change - Change in the name 
24/02/2016 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
